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ABSTRACT
Objective: To develop and validate a simple, selective, precise, and accurate method for the estimation of dapagliflozin using reversed-phase high-
performance liquid chromatography (RP-HPLC) technique in bulk and tablet formulation.
Methods: The proposed method utilizes chromatographic conditions hypersil BDS (250 mm × 4.6 mm, 5 µ), mobile phase was buffer:acetonitrile 
(60:40) ratio, flow rate was maintained 1 ml/minute, column temperature was set at 30°C, detection wave length was 245 nm, and diluent was mobile 
phase.
Results: By injecting 5 times of the standard solution system suitability parameters were studied, and results were found well under the acceptance 
criteria. The linearity study was performed by taking 25-150% levels, and the R2 value was found to be 0.999, precision was found to be 0.5 for 
repeatability and 0.31 for intermediate precision. The % recovery was found to be 99.89%. Limit of detection and limit of quantitation were found to 
be 0.60 µg/ml and 1.81 µg/ml, respectively. The % purity was found to be 99.71%. Degradation study on dapagliflozin was performed and concluded 
that the purity threshold was more than purity angle and within the acceptable range.
Conclusion: The developed RP-HPLC method for dapagliflozin was found to be simple, precise, accurate, reproducible, and cost effective. Statistical 
analysis of the developed method conforms that the proposed method is an appropriate and it can be useful for the routine analysis. This method gives 
the basic idea to the researcher who is working in area such as product development and finish product testing.
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INTRODUCTION
Dapagliflozin is a novel inhibitor of renal sodium-glucose 
cotransporter 2, which allows an insulin-independent approach to 
improve Type-II diabetes hyperglycemia [1]. It is a C-aryl glucoside 
derivative and is chemically known as (1s)-1, 5-anhydro-1-C-[4-chloro-
3-[(4-ethoxyphenyl) methyl] phenyl]-D- glucitol (Fig. 1).
As per the past literature review, dapagliflozin was estimated by 
different chromatographic methods such as liquid chromatography–
mass spectrometry [2], normal phase high-performance liquid 
chromatography (HPLC) [3,4], and reversed-phase HPLC (RP-
HPLC) for simultaneous determination [5,6] and by different 
spectroscopic methods such as ultraviolet (UV) [7], UV first derivative 
spectroscopy [6,8], and moreover several methods were there for the 
determination of its pharmacologic action [9-15].
Hence, the present paper reports that to develop and validate an 
accurate method for the estimation of dapagliflozin by RP-HPLC method 
and its forced degradation studies using a different mobile phase ratio 
that is a mixture of orthophosphoric acid buffer and acetonitrile in 




Dapagliflozin was obtained as gift sample from Manus Aktteva 
Biopharma, Gujarat. Acetonitrile, methanol, and water used were of 
HPLC grade.
Selection of wavelength
Wavelength for detection was selected by obtaining absorption spectra of 
dapagliflozin in methanol using double beam UV-visible spectrophotometer. 
The spectrum of dapagliflozin in UV range was showed in Fig. 2 and 
concluded that dapagliflozin shows strong absorption at 245 nm.
Instrumentation
Chromatography was performed on Waters HPLC 2996 system with 
Empower- 2 Software, equipped with a photodiode array detector 
(PDA) detector and chromatographic separation was performed using 
BDS column (250 × 4.6 mm, 5 µ) [16].
Chromatographic conditions
An HPLC system (make:waters, model 2996) which is operated using 
a Software Empower - 2, fitted with BDS column and PDA detector 
(at 245 nm) was used for the analysis. Gradient run with a flow rate 
1 ml/minute, temperature 30°C and injection volume 10 µl was 
preferred for resolving the drug.
Preparation of mobile phase
A mixture (60:40) of orthophosphoric acid buffer and acetonitrile was 
used as mobile phase.
Buffer preparation
About 1 ml of concentration orthophosphoric acid was diluted to 
1000 ml with water.
Diluents
Initially, the drug was dissolved in methanol, and water HPLC grade was 
used as a diluent for further dilutions.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Stock solution preparation
Weighed accurately about 10 mg of dapagliflozin working standard and 
transferred into 10 ml volumetric flask. To this 7 ml of diluent was added 
and sonicated for 5 minutes. Further, volume made with the diluent.
Standard solution preparation
Weighed accurately about 10 mg of dapagliflozin working standard 
and transferred into 10 ml volumetric flask. To this 7 ml of diluent was 
added, sonicated for 5 minutes and diluted to volume with diluent. 
Further diluted 1-10 ml with diluent.
Sample preparation
Crushed and powdered 20 tablets. Weighed and transferred equivalent to 
five tablets powder of the dapagliflozin into 50 ml volumetric flask, 30 ml 
of diluent was added, sonicated to dissolve for 15 minutes and diluted to 
volume with diluent. Further diluted the filtrate 1-10 ml with diluent.
Assay of marketed formulation
Assay of the marketed formulation was carried out by injecting sample 
corresponding to equivalent weight into HPLC system. Then, the 
percent purity was found by following formula, and the results were 
shown in Table 1.
Samplearea StandarddilutionfactorAssay= × ×
Standardarea Sampledilutionfactor
AverageWt of tab ×Potencyof std×100
Labelclaim
Validation parameters
The validation of an analytical method confirms the characteristics of 
the method to fulfill the requirements of the application domain. The 
method was validated according to the ICH guidelines for specificity, 
linearity, precision, recovery, and stability [17].
System suitability
A standard solution of dapagliflozin working standard was prepared 
as per procedure and injected 5 times into the HPLC system. Then, 
the system suitability parameters were evaluated from standard 
chromatograms obtained. The % relative standard deviations (RSD) of 
retention time, tailing factor, theoretical plates, and peak areas from five 
replicate injections was within range and results were shown in Table 2, 
and the chromatogram was shown in Fig. 3.
Specificity
Specificity is the ability of a method to discriminate between the 
intended analyte(s) and other components in the sample, to check 
whether there is placebo, blank, impurity, and degradants interference 
at analyte concentration. Volume of 10 µl of working placebo sample 
solution was injected, and the chromatogram was recorded. Specificity 
graph was shown in Fig. 4.
Linearity
To demonstrate linearity of the assay method, five standard solutions 
with concentrations of about 25-150 ppm of dapagliflozin was injected. 
Then, a graph was plotted between concentrations and peak area. 
Linearity plot was shown in Fig. 5.
Accuracy
Three concentrations of 50%, 100%, and 150% were injected in a 
triplicate manner then % recovery and % RSD were calculated and 
shown in Table 3.
Fig. 1: Structure of dapagliflozin
Fig. 2: Ultraviolet spectrum of dapagliflozin




Assay Average SD % RSD






SD: Standard deviation, RSD: Relative standard deviations 
Table 2: System suitability parameters of dapagliflozin
Peak name RT USP plate 
count
Peak area USP tailing
Dapagliflozin 2.789 5030 736119 1.02
Dapagliflozin 2.796 5208 730712 1.02
Dapagliflozin 2.796 5013 734185 1.01
Dapagliflozin 2.797 5072 735891 1.01
Dapagliflozin 2.800 5134 731267 1.02




RSD: Relative standard deviations, SD: Standard deviations
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Precision
Precision was estimated by studying repeatability, intra- and interday 
tests by injecting 100 ppm concentration of dapagliflozin. The results 
were calculated as standard deviation, relative standard deviation and 
shown in Table 4.
Limit of detection (LOD)
LOD is the lowest level of concentration of analyte in the sample that 
can be detected, though not necessarily quantitated. It can be calculated 
from the below formula, and the results are shown in Table 5.
LOD = 3.3 σ/S
Where,
σ = Standard deviation of the response,
S = Slope of calibration curve.
Limit of quantitation (LOQ)
LOQ is the lowest concentration of analyte in a sample that may be 
determined with acceptable accuracy and precision when the required 
procedure is applied. It can be calculated from the below formula, and 
the results are shown in Table 6.
LOQ = 10 σ/S
Where,
σ = Standard deviation of the response,
S = Slope of calibration curve.
Robustness
It is the capacity of the method to remain unaffected by small but 
deliberate variations in method parameters. The analysis was 
performed by slightly changing the temperature, mobile phase 
composition and flow rate. The results were calculated as % RSD and 
were given in Table 7.
Degradation studies
Acid degradation studies
To 1 ml of stock solution of dapagliflozin, 1 ml of 2 N hydrochloric acid 
was added and refluxed for 30 minutes at 60°C. Then, the resultant 
solution was diluted to obtain 100 µg/ml solution. Then, 10 µl solution 
was injected into the system. The chromatogram was recorded to assess 
the stability of sample which is shown in Fig. 6; % of degradation was 
calculated and shown in Table 8.
Alkali degradation studies
To 1 ml of stock solution dapagliflozin, 1 ml of 2N sodium hydroxide was 
added and refluxed for 30 minutes at 60°C. Then, the resultant solution 
was diluted to obtain 100 µg/ml solution, and 10 µl was injected into the 
system, and the chromatograms were recorded to assess the stability of 
sample which is shown in Fig. 6, % of degradation was calculated and 
shown in Table 8.
Oxidation degradation studies
To 1 ml of stock solution of dapagliflozin, 1 ml of 20% hydrogen 
peroxide (H2O2) was added separately. The solutions were kept for 
30 minutes at 60°C. Then, the resultant solution was diluted to obtain 
100 µg/ml solution, and 10 µl was injected into the system, and the 
chromatograms were recorded to assess the stability of sample which 
is shown in Fig. 6, % of degradation was calculated and shown in 
Table 8.
Thermal degradation studies
The standard drug solution was placed in oven at 60°C for 6 hrs to 
study dry heat degradation. Then, the resultant solution was diluted 
to 100 µg/ml solution, and 10 µl was injected into the system, and the 
chromatograms were recorded to assess the stability of sample which is 
shown in Fig. 6, % of degradation was calculated and shown in Table. 8.Fig. 3: System suitability chromatogram of dapagliflozin
Fig. 4: Specificity chromatogram of standard dapagliflozin
Table 3: Accuracy data
Spiked concentration (%) Amount taken PPM Amount recovered PPM % Recovery Average SD % RSD
50 50 50.01 100.02
50 50 50.17 100.34 99.82 0.63 0.63
50 50 49.55 99.11
100 100 100.30 100.30
100 100 99.84 99.84 100.00 0.26 0.26
100 100 99.87 99.87
150 150 150.97 100.65
150 150 149.18 99.40 99.83 0.71 0.71




RSD: Relative standard deviations, SD: Standard deviations
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Photo stability (UV) degradation studies
The photochemical stability of the drug was also studied by exposing the 
100 µg/ml solution to UV light by keeping the beaker in UV Chamber for 
7 days or 200 Watt hrs/m2 in photo stability chamber. For HPLC study, 
from this, 10 µl was injected into the system, and the chromatograms 
were recorded to assess the stability of sample which is shown in Fig. 6, 
% of degradation was calculated and shown in Table 8.
Neutral (water) degradation studies
Stress testing under neutral conditions was studied by refluxing the 
drug in water for 6 hrs at a temperature of 105°C. For HPLC study, the 
resultant solution was diluted to 100 µg/ml solution and 10 µl was 
injected into the system and the chromatograms were recorded to 
assess the stability of sample which is shown in Fig. 6, % of degradation 
was calculated and shown in Table 8.
RESULTS AND DISCUSSION
The selected drug dapagliflozin was estimated by RP-HPLC method and 
the forced degradation studies were performed as per ICH Guidelines. 
The method was optimized in the mobile phase ratio of Buffer (Ortho 
phosphoric acid buffer): Acetonitrile (60:40). The detection was 
carried out at the wavelength of 245 nm (shown in Fig. 2) with a 
retention time 2.789 min and with peak asymmetry of 1.02 (shown in 
Fig. 3 and Table 2).
The method was validated as per ICH guidelines. The linearity range for 
Dapagliflozin was 25–150 µg/ml with R2 (correlation co-efficient) value 
of 0.999 (shown in Fig. 5). The percentage RSD for method and system 
precision was <2% (shown in Table 2). The method has been validated 
in assay of dosage forms. The accuracy of the method was validated by 
recovery studies and was found to significant and under specification 
limits, with % Recovery 99.11– 100.65 % (within acceptable range (98–
102%) (shown in Table 3). The assay results were found to be 99.71% 
(shown in Table 1) (i.e., within 98–102%). LOD and LOQ were found 
to be 0.60 µg/ml and 1.81 µg/ml respectively (Table 5 and Table 6). 
The method also passes the specifications for robustness parameters 
(shown in Table 7).
 The sample solutions were subjected to acid, base, oxidative, thermal, 
UV, Neutral degradations. The % degradation in acid (7.35 %), basic 
Fig. 5: Linearity plot of dapagliflozin
Fig. 6: Degradation studies of dapagliflozin
Table 4: Precision reports for dapagliflozin
Precision SD % RSD Acceptance limit
System precision 2431.1 0.34 NMT 2%
Repeatability 3608.3 0.5 NMT 2%
Intermediate precision 2156.2 0.31 NMT 2%
RSD: Relative standard deviations, SD: Standard deviations
Table 5: LOD of dapagliflozin
Drug name SD Slope LOD (µg/ml)
Dapagliflozin 3129 17296 0.60
SD: Standard deviation, LOD: Limit of detection
Table 6: LOQ of dapagliflozin
Drug name SD Slope LOQ (µg/ml)
Dapagliflozin 3129 17296 1.81
SD: Standard deviation, LOQ: Limit of quantification
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(6.90%), oxidative (5.53%), hydrolytic (0.78%), thermal (4.43%), 
photolytic (1.91%) was found (shown in Table 8).
CONCLUSION
The developed RP-HPLC method for dapagliflozin was found to be 
simple, precise, accurate, reproducible, and cost effective. Statistical 
analysis of the developed method conforms that the proposed method 
is an appropriate and it can be useful for the routine analysis. This 
method gives the basic idea to the researcher who is working in area 
such as product development and finish product testing. The developed 
method can also be used regular for the in-process quality control of the 
sample. This method gives the sound knowledge about stability studies. 
The results of the forced degradation studies show the major route of 
degradation is in acid hydrolysis followed by alkali, oxidation, thermal, 
photolytic, and neutral, respectively. The developed method concludes 
that the dapagliflozin was found to be stable in neutral, photolytic, 
thermal and oxidative stress conditions, and unstable in acidic and 
alkali conditions.
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Table 7: Robustness data of dapagliflozin

















































RSD: Relative standard deviations, SD: Standard deviations
Table 8: Results of degradation data of dapagliflozin
Degradation condition Exposure Time % Drug degraded Purity angle Purity threshold
Acid 2N HCl/60°C 30 minutes 7.35 0.115 0.311
Alkali 2N NaOH/60°C 30 minutes 6.90 0.236 0.361
Oxidation 20% H2O2/60°C 30 minutes 5.53 0.361 0.517
Thermal At 60°C 6 hrs 4.43 0.271 0.320
UV UV chamber 7 days 1.91 0.113 0.303
Water At room temp 6 hrs 0.78 0.111 0.308
UV: Ultraviolet
